YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Yarrow Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$19.98+1.67 (+9.12%)
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Yarrow Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Market Cap | $53.34M | $166.30M |
| Enterprise Value | $30.42M | $88.19M |
| PS Ratio | 93.58 | 3.65 |
| PB Ratio | 2.42 | 2.03 |
| P/TBV Ratio | 2.42 | 2.29 |
Enterprise value
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| EV / Sales | 53.36 | 2.51 |
Income (trailing twelve months)
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Revenue | $570.00K | $58.34M |
| Operating Income | -$29.75M | -$21.40M |
| Pretax Income | -$26.73M | -$14.34M |
| Net Income | -$26.48M | -$22.46M |
| EBITDA | -$29.73M | -$16.91M |
| EPS (Diluted) | -$31.00 | -$0.83 |
Margins
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Operating Margin | -5219.1% | -44.0% |
| Pretax Margin | -4689.8% | -13.3% |
| Profit Margin | -4646.1% | -40.2% |
| EBITDA Margin | -5215.1% | -30.2% |
| FCF Margin | -5811.2% | -9.27% |
Returns
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -86.9% | -53.2% |
| Return on Assets (ROA) | -77.5% | -40.9% |
| Return on Capital Employed (ROCE) | -134.8% | -38.1% |
Growth
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 13.8% | 5.96% |
| Revenue Growth (3Y CAGR) | 6.12% | 2.25% |
| Revenue Growth (5Y CAGR) | -51.4% | 6.48% |
Balance sheet
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $22.93M | $61.43M |
| Net Cash (Debt) | $22.93M | $15.35M |
| Net Cash Per Share | $8.59 | $0.66 |
| Equity (Book Value) | $22.06M | $49.09M |
| Book Value Per Share | $8.26 | $1.37 |
| Tangible Book Value | $22.06M | $23.52M |
| Working Capital | $21.98M | $76.81M |
Financial position
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Current Ratio | 15.26 | 3.34 |
| Quick Ratio | 14.87 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$33.12M | -$12.35M |
| Capital Expenditures | $0 | -$1.08M |
| Free Cash Flow | -$33.12M | -$20.22M |
| FCF Per Share | -$12.41 | -$0.42 |
Efficiency
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.39 |
| Revenue Per Employee | $57.00K | $404.87K |
| Profits Per Employee | -$2.65M | -$703.34K |
| Employee Count | 10 | 74 |
Dividends and yields
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -49.6% | -23.3% |
| FCF Yield | -62.1% | -8.72% |
Shares
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 2,669,750 | 58,127,000 |
| Shares Change (YoY) | 0.42% | 10.9% |
| Shares Change (QoQ) | 0.19% | 0.54% |
| Float | 477,482 | 49,136,700 |
| Shares Held by Insiders | 82.1% | 11.6% |
Taxes
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Income Tax | $4.00K | $79.87K |
Scores
| Measure | Yarrow Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -27.59 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Yarrow Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.